Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Depreciation and Depletion: 2017-2024

Historic Depreciation and Depletion for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $143,000.

  • Mereo BioPharma Group's Depreciation and Depletion fell 61.00% to $39,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $159,000, marking a year-over-year decrease of 49.04%. This contributed to the annual value of $143,000 for FY2024, which is 28.50% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Depreciation and Depletion stood at $143,000 for FY2024, which was down 28.50% from $200,000 recorded in FY2023.
  • Over the past 5 years, Mereo BioPharma Group's Depreciation and Depletion peaked at $200,000 during FY2022, and registered a low of $143,000 during FY2024.
  • In the last 3 years, Mereo BioPharma Group's Depreciation and Depletion had a median value of $200,000 in 2023 and averaged $181,000.
  • Data for Mereo BioPharma Group's Depreciation and Depletion shows a maximum YoY fell of 28.50% (in 2024) over the last 5 years.
  • Over the past 3 years, Mereo BioPharma Group's Depreciation and Depletion (Yearly) stood at $200,000 in 2022, then remained steady at $200,000 in 2023, then decreased by 28.50% to $143,000 in 2024.